IL2 and rheumatic disorder: Although the findings here are less clear compared to those in SLE and in part even inconsistent, it appears justified to suppose, in consideration of the immune pathogenesis of these diseases, that expansion of the Treg population or inhibition of Tfh and Th17 cell differentiation by low-dose IL-2 therapy could be a potential treatment option for a large variety of autoimmune and rheumatic diseases.